/AZRX

AZRX Stock - AzurRx BioPharma, Inc.

Q: What is the analyst price target for AZRX?

Analyst price target information is not currently available for AZRX.

Q: What is AZRX's market cap?

Market capitalization information is not currently available for AZRX.

Healthcare|Biotechnology|NASDAQ

$3.45+2.07%

+$0.07 (+2.07%) • Sep 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.80

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AZRX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.51

52W High$26.30

52W Low$2.68

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2020	FY2019	FY2018	FY2017
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-15,621,274	$-26,432,768	$-14,743,747	$-13,431,771	$-10,081,184
Net Income	$-18,059,336	$-32,671,466	$-15,177,686	$-13,533,617	$-11,096,383
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-5.33	$-5.90	$-6.77	$-8.77	$-10.44

Company Overview

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Visit Website

Earnings History & Surprises

AZRX

Beat Rate

22%

Last 18 quarters

Avg Surprise

-53.1%

EPS vs Estimate

Beats / Misses

4/13

1 met exactly

Latest EPS

$-1.60

Q3 2021

EPS Surprise History

Q4 19

-8.3%

$-1.70vs$-1.57

Q1 20

+70.0%

$-0.48vs$-1.60

Q2 20

-70.9%

$-2.00vs$-1.17

Q3 20

-60.4%

$-1.70vs$-1.06

Q4 20

-245.6%

$-4.70vs$-1.36

Q1 21

-127.9%

$-3.10vs$-1.36

Q2 21

-94.4%

$-1.40vs$-0.72

Q3 21

-122.2%

$-1.60vs$-0.72

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2021	Aug 16, 2021	$-0.72	$-1.60	-122.2%	✗ MISS
Q2 2021	May 24, 2021	$-0.72	$-1.40	-94.4%	✗ MISS
Q1 2021	Mar 31, 2021	$-1.36	$-3.10	-127.9%	✗ MISS
Q4 2020	Nov 16, 2020	$-1.36	$-4.70	-245.6%	✗ MISS
Q3 2020	Aug 14, 2020	$-1.06	$-1.70	-60.4%	✗ MISS
Q2 2020	May 15, 2020	$-1.17	$-2.00	-70.9%	✗ MISS
Q1 2020	Mar 30, 2020	$-1.60	$-0.48	+70.0%	✓ BEAT
Q4 2019	Nov 14, 2019	$-1.57	$-1.70	-8.3%	✗ MISS
Q3 2019	Aug 13, 2019	$-0.21	$-0.25	-19.0%	✗ MISS
Q2 2019	May 15, 2019	$-0.18	$-0.26	-44.4%	✗ MISS
Q2 2019	Apr 1, 2019	$-0.18	$-0.24	-33.3%	✗ MISS
Q4 2018	Nov 9, 2018	$-0.20	$-0.15	+25.0%	✓ BEAT
Q3 2018	Aug 13, 2018	$-0.24	$-0.22	+8.3%	✓ BEAT
Q2 2018	May 14, 2018	$-0.18	$-0.29	-61.1%	✗ MISS
Q1 2018	Mar 16, 2018	$-0.25	$-0.21	+16.0%	✓ BEAT
Q4 2017	Nov 13, 2017	$-0.17	$-0.28	-64.7%	✗ MISS
Q3 2017	Aug 14, 2017	$-0.27	$-0.27	0.0%	= MET
Q2 2017	Jun 29, 2017	$-0.13	$-0.29	-123.1%	✗ MISS
Q4 2016	Dec 31, 2016	—	$-5.85	—	—
Q4 2016	Nov 25, 2016	—	$-3.24	—	—

Frequently Asked Questions about AZRX

What is AZRX's current stock price?

AzurRx BioPharma, Inc. (AZRX) is currently trading at $3.45 per share. The stock has moved +2.07% today.

What is the analyst price target for AZRX?

No analyst price targets are currently available for this stock.

What sector is AzurRx BioPharma, Inc. in?

AzurRx BioPharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is AZRX's market cap?

AzurRx BioPharma, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does AZRX pay dividends?

No, AzurRx BioPharma, Inc. does not currently pay a dividend to shareholders.